Dr. Gabrielle Lyon
speaker
18,769 appearances
47 recordings
13 series
first heard Nov 2024
last heard 10 Sep
Dr. Gabrielle Lyon’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 41 in all, peaking in Jul 2026 with 9.
Appearances
And in the major weight loss trials, GI disorders were reported in 74 to 84% of participants on one particular medication.
Nearly half of patients discontinue GLP1 therapy within one year, with GI side effects, you guessed it, being the primary driver.
So if we layer on GLP1 use, these drugs reduce appetite, they increase early satiety, they decrease overall food intake, and that's how they're supposed to work.
But of course, when total food volume drops, fiber intake drops with it.
And a secondary analysis of lariblutide, a randomized control trial, found that patients on GLP1 therapy underconsumed multiple key nutrients relative to the recommendations.
Now, they weren't just eating less.
They were eating less of the things that they need the most.
So we have a population that's already fiber deficient.
We put them on a medication that further reduces their food intake and causes GI symptoms that make fiber even harder to eat.
And then, rightly, we wonder why.
They're constipated, bloated, losing muscle mass.
Also losing fat.
To understand this paradox, let's just briefly touch on the GLP1 receptor, Agnes, and how it works.
It works in part.
You take these medications and they slow gastric emptying, meaning the food stays in your system longer.
And it also slows motility, meaning the movement of the gut.
This is not a side effect.
I just want to be very clear.
This is a mechanism of action as to how these medications work.
They reduce glucose absorption.
Showing 2601–2620 of 18,769 · page 131 of 939
← Previous
Next →